Genitourinary Cancers | Specialty

Does Immuno-Oncology Therapy Have a Larger Role in the Urology Clinic?

June 21st 2019

The FDA approved indications in urologic cancers for 6 immune checkpoint inhibitors since 2015. That is unquestionably a good thing for patients, but the rise of these agents means that the role of the urologist in cancer care is changing, and some urologists are still on the fence about these agents.

Telaglenastat Added to Everolimus Doubles PFS in Heavily Pretreated RCC

June 18th 2019

Combining telaglenastat (CB-839) with everolimus (Afinitor) doubled the median progression-free survival versus everolimus alone in heavily pretreated patients with advanced renal cell carcinoma.

Dr. Tagawa on Next Steps With Sacituzumab Govitecan in Advanced Urothelial Carcinoma

June 17th 2019

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses next steps with sacituzumab govitecan in advanced urothelial carcinoma.

The Fight to Save the Bladder Turns to Genomics

June 14th 2019

The search for effective alternatives to radical cystectomy (RC) in patients with bladder cancer has lasted more than 3 decades. Progress has been slow, but investigators have proved that a combination of radiation, chemotherapy, and maximal transurethral resection of the bladder tumor works as well as RC in carefully selected patients.

Immune System Agents May Move Into Earlier Settings in GU Cancers

June 13th 2019

Over the past 5 years, medical oncologists have witnessed the revolutionary impact of immunotherapy on patients with advanced urologic malignancies. Over the next 5 years, these therapies likely will similarly transform urologic surgical care.

Dr. Bochner on Future Treatment Strategies in Early-Stage NMIBC

June 12th 2019

Bernard H. Bochner, MD, FACS, Sir Murray F. Brennan Chair in Surgery, Memorial Sloan Kettering Cancer Center, discusses future treatment strategies in early-stage non–muscle invasive bladder cancer.

Avelumab/Axitinib Combo Biomarker Analysis May Lend Insight to Complex RCC Landscape

June 11th 2019

Toni Choueiri, MD, discusses the biomarker analysis results from JAVELIN Renal 101 and provided insight on where the renal cell carcinoma field stands following pivotal data presented at the 2019 ASCO Annual Meeting.

Dr. Choueiri on the Subgroup Analysis of the JAVELIN Renal 101 Trial in RCC

June 11th 2019

Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Associate Professor of Medicine, Harvard Medical School, discusses findings from the subgroup analysis of the phase III JAVELIN Renal 101 trial in advanced renal cell carcinoma (RCC).

Dr. McGregor on Advances Made in the Adjuvant Setting of RCC

June 8th 2019

Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses advances made in the adjuvant setting of renal cell carcinoma (RCC).

Dr. Sonpavde on the Potential for Neoadjuvant Immunotherapy in Bladder Cancer

June 7th 2019

Guru P. Sonpavde, MD, director of Bladder Cancer at Dana-Farber Cancer Institute, discusses the potential for neoadjuvant immunotherapy in bladder cancer.

Dr. McDermott on the Promise of Pembrolizumab in Non-Clear Cell RCC

June 6th 2019

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the promise of single-agent pembrolizumab in advanced non–clear cell renal cell carcinoma.

Dr. Petrylak on Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma

June 4th 2019

Daniel P. Petrylak, MD, professor of medicine and urology at Yale Cancer Center, 2017 Giant of Cancer Care in Genitourinary Cancers, discusses the phase II EV-201 trial of enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy or a PD-1/PD-L1 checkpoint inhibitor.

Dr. Shuch on Caveats of Avelumab/Axitinib Combination in RCC

June 4th 2019

Brian M. Shuch, MD, director, Kidney Cancer Program, Alvin & Carrie Meinhardt Endowed Chair of Kidney Cancer Research, University of California, Los Angeles Institute of Urologic Oncology, discusses caveats of the avelumab plus axitinib combination in frontline advanced renal cell carcinoma.

ASCO 2019: Dr. Plimack Highlights Practice-Changing Data for Genitourinary Cancers

June 2nd 2019

ASCO 2019: Dr. Ferris Discusses the Latest Data in Head and Neck Cancer

June 2nd 2019

Dr. Tolaney Highlights New Breast Cancer Combination Therapies

June 2nd 2019

ASCO 2019: Dr. Monk on Promising Abstracts in Gynecologic Malignancies

June 2nd 2019

ASCO 2019: Dr. Horn Highlights Progress in Lung Cancer

June 2nd 2019

ASCO 2019: Dr. Shah Covers Potentially Practice-Changing GI Cancer Studies

June 2nd 2019

ASCO 2019: Dr. Tagawa Highlights Key Prostate Cancer Data

June 2nd 2019